Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
11 pending office actions • 7 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Research Development Foundation has 11 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 11 distinct examiners and 7 distinct art units, indicating substantial examiner dispersion with some concentration within technical groups.
LAU, MICHAEL J is the busiest examiner, with 1 pending matter. Since the examiner count matches the pending-action count, portfolio management should emphasize individual examiner histories, while art-unit grouping can help identify broader biotechnology prosecution patterns.
The profile supports a coordinated docketing process that preserves matter-level analysis. Counsel should avoid assuming that one amendment or argument will transfer across all assignments, because the matters are distributed among multiple examiners and art units.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (18%) |
| §112 only | 2 (18%) |
| Double-patenting + other | 2 (18%) |
| Multi-statute (no §101) | 5 (45%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LAU, MICHAEL J | 1 | 72.3% | +23.2% |
| RAHMAN, MASUDUR | 1 | 72.9% | +31.7% |
| ARIANI, KADE | 1 | 75.0% | +32.0% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.2% | +38.9% |
| BUTTICE, AUDREY L | 1 | 46.6% | +26.0% |
| BEHARRY, ZANNA MARIA | 1 | 25.0% | +56.3% |
| FAN, LYNN Y | 1 | 47.3% | +49.8% |
| NOBLE, MARCIA STEPHENS | 1 | 67.2% | +39.5% |
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
| ANJARIA, SHREYA PARAG | 1 | 53.7% | +26.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18332571 | ENGINEERED FCRIIB SELECTIVE IGG1 FC VARIANTS AND USES THEREOF | BUTTICE, AUDREY L | 28d overdue |
| 18248739 | METHODS FOR MAKING AND USING DIFFERENTIATED NEURAL CELLS | BEHARRY, ZANNA MARIA | 19d overdue |
| 18980005 | SYSTEMS AND METHODS FOR CORONARY OCCLUSION TREATMENT | LAU, MICHAEL J | — |
| 18855867 | METHODS FOR MAKING AND USING DIFFERENTIATED NEURAL CELLS | RAHMAN, MASUDUR | — |
| 17611315 | METHODS AND APPARATUS FOR HIGH-SPEED AND HIGH-ASPECT RATIO LASER SUBTRACTIVE MATERIAL PROCESSING | FEDORKY, MEGAN TAYLOR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17548467 | SYSTEMS AND METHODS FOR LASER-INDUCED CALCIUM FRACTURES | ANJARIA, SHREYA PARAG | 134d overdue |
| 18060134 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF BONE DISORDERS | FAN, LYNN Y | 79d overdue |
| 18052476 | SERINE PROTEASE MOLECULES AND THERAPIES | LI, RUIXIANG | 77d overdue |
| 18332571 | ENGINEERED FCRIIB SELECTIVE IGG1 FC VARIANTS AND USES THEREOF | BUTTICE, AUDREY L | 28d overdue |
| 18248739 | METHODS FOR MAKING AND USING DIFFERENTIATED NEURAL CELLS | BEHARRY, ZANNA MARIA | 19d overdue |
| 18060183 | ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS | NOBLE, MARCIA STEPHENS | 17d overdue |
| 18413541 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES AND DISORDERS | PAGUIO FRISING, MICHELLE F | 84d |
| 18980005 | SYSTEMS AND METHODS FOR CORONARY OCCLUSION TREATMENT | LAU, MICHAEL J | — |
| Art Unit | Apps |
|---|---|
| 3796 | 3 |
| 1651 | 2 |
| 1632 | 2 |
| 1633 | 1 |
| 1647 | 1 |
| 1759 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18980005 | SYSTEMS AND METHODS FOR CORONARY OCCLUSION TREATMENT | LAU, MICHAEL J | 3796 | §103§112 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18855867 | METHODS FOR MAKING AND USING DIFFERENTIATED NEURAL CELLS | RAHMAN, MASUDUR | 1633 | §102§103 | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18619514 | COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES | ARIANI, KADE | 1651 | §103§112DP | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18413541 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES AND DISORDERS | PAGUIO FRISING, MICHELLE F | 1651 | §103DP | Non-Final OA | 84d | Pending | Jan 16, 2024 |
| 18332571 | ENGINEERED FCRIIB SELECTIVE IGG1 FC VARIANTS AND USES THEREOF | BUTTICE, AUDREY L | 1647 | §103§112 | Final Rejection | 28d overdue | Pending | Jun 09, 2023 |
| 18248739 | METHODS FOR MAKING AND USING DIFFERENTIATED NEURAL CELLS | BEHARRY, ZANNA MARIA | 1632 | §103§112Other | Final Rejection | 19d overdue | Pending | Apr 12, 2023 |
| 18060134 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF BONE DISORDERS | FAN, LYNN Y | 1759 | §103 | Non-Final OA | 79d overdue | Pending | Nov 30, 2022 |
| 18060183 | ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS | NOBLE, MARCIA STEPHENS | 1632 | §112 | Final Rejection | 17d overdue | Pending | Nov 30, 2022 |
| 18052476 | SERINE PROTEASE MOLECULES AND THERAPIES | LI, RUIXIANG | 1674 | §112 | Non-Final OA | 77d overdue | Pending | Nov 03, 2022 |
| 17548467 | SYSTEMS AND METHODS FOR LASER-INDUCED CALCIUM FRACTURES | ANJARIA, SHREYA PARAG | 3796 | §103 | Non-Final OA | 134d overdue | Pending | Dec 10, 2021 |
| 17611315 | METHODS AND APPARATUS FOR HIGH-SPEED AND HIGH-ASPECT RATIO LASER SUBTRACTIVE MATERIAL PROCESSING | FEDORKY, MEGAN TAYLOR | 3796 | §103§112 | Non-Final OA | — | Pending | Nov 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialResearch Development Foundation has 11 pending office actions as of October 2026, spread across 7 art units and 11 examiners.
Michael J Lau has the most, with 1 of Research Development Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
